Positive Results for Patisiran in ATTR Amyloidosis Cardiomyopathy

The RNAi therapeutic patisiran improves functional capacity and quality of life in ATTR amyloidosis with cardiomyopathy, topline results of APOLLO-B show. The company will seek an FDA supplemental NDA.
Medscape Medical News
The RNAi therapeutic patisiran improves functional capacity and quality of life in ATTR amyloidosis with cardiomyopathy, topline results of APOLLO-B show. The company will seek an FDA supplemental NDA.
Medscape Medical News